Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cairn Diagnostics, formerly known as Advanced Breath Diagnostics, is a medical technology company that develops and commercializes non-invasive breath tests for gastrointestinal and metabolic disorders. The company's primary product is the 13C-Spirulina Gastric Emptying Breath Test (GEBT), an FDA-approved diagnostic tool for gastroparesis that utilizes stable isotope technology. Unlike traditional scintigraphy, GEBT is non-radioactive and can be administered in a physician's office, providing a more accessible diagnostic option for patients. Cairn's platform is designed to measure physiological functions through the analysis of exhaled breath, with ongoing research into additional indications. The company focuses on providing standardized, validated testing solutions that improve patient management in gastroenterology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Advanced Breath Diagnostics.